This is an old revision of this page, as edited by Pashihiko (talk | contribs) at 08:24, 11 January 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 08:24, 11 January 2011 by Pashihiko (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Intravitreal injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| KEGG | |
| Chemical and physical data | |
| Formula | C204H263N63O114P20S20 |
| Molar mass | 6682.4 g/mol g·mol |
Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was licenced by the FDA for CMV in Aug 1998.
It is a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:
- 5'-GCG TTT GCT CTT CTT CTT GCG-3'
Mechanism
It is an oligonucleotide that blocks translation of viral mRNA by binding to a coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.
Administration
It is available as an intraocular injection in a concentration of 6.6 mg/mL.
See also
References
- Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (1998). "Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMC 105584. PMID 9559825.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Roush W (1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327.
{{cite journal}}: Unknown parameter|month=ignored (help) - Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. p. 817. ISBN 0-07-145153-6.
Further reading
- Grillone, LR; Lanz, R (2001). "Fomivirsen". Drugs Today (Barc). 37 (4): 245–255. PMID 12768225.
- Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet. 41 (4): 255–60. PMID 11978144.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol. 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781.
{{cite journal}}:|first1=has generic name (help) - Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care. 4 (10): 14–6. PMID 11365956.
External links
- MedlinePlus DrugInfo uspdi-203675
- Diseases Database (DDB): 31313
- "Vitravene (Fomivirsen) Drug Information: Uses, Side Effects, Drug Interactions and Warning". RxList. 2004-12-08. Retrieved 2009-05-20.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help)
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |
| DNA virus antivirals (primarily J05, also S01AD and D06BB) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baltimore I |
| ||||||||||||||||||||
| Hepatitis B (VII) | |||||||||||||||||||||
| Multiple/general |
| ||||||||||||||||||||
| |||||||||||||||||||||